Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients
Authors:
- Uta BruntschUBUta Bruntsch
- 1 July 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (7) , 905-909
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Renal disease after mitomycin c therapyCancer, 1981
- Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinomaCancer, 1981
- MITOMYCIN-INDUCED HAEMOLYSIS AND RENAL FAILUREThe Lancet, 1980
- RASH, NEPHRITIS, HYPERTENSION, AND HÆMOLYSIS IN PATIENT ON 5-FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN-CThe Lancet, 1980
- INTRAVASCULAR HÆMOLYSIS AND RENAL IMPAIRMENT AFTER BLOOD TRANSFUSION IN TWO PATIENTS ON LONG-TERM 5-FLUOROURACIL AND MITOMYCIN-CThe Lancet, 1980
- Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracilCancer, 1980
- Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin CCancer, 1979
- Microangiopathic Hemolytic Anemia in Metastatic CarcinomaAnnals of Internal Medicine, 1973
- Microangiopathic Haemolytic Anaemia and Mucin‐forming AdenocarcinomaBritish Journal of Haematology, 1970
- Microangiopathic Hemolytic Anemia in Carcinoma of the StomachGastroenterology, 1967